Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-04-23-Speech-1-125"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2007-04-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Advanced therapy medicinal products (debate)2
dcterms:Language	"sk"^^xsd:language2
lpv:document identification number	"en.20070423.17.1-125"2
lpv:hasSubsequent	lp_eu:2007-04-23-Speech-1-1272
lpv:speaker	lp:Zita Pleštinská2
lpv:spokenAs	substitute; Delegation for relations with Australia and New Zealand (2007-03-14--2009-07-13)3 substitute; REGI (2007-01-31--2009-07-13)3 member; IMCO (2007-01-31--2009-07-13)3 member; EPP-ED (2004-07-20--2009-07-13)3 member; FEMM (2007-01-31--2009-07-13)3 member; Delegation to the EU-Ukraine Parliamentary Cooperation Committee (2004-09-15--2009-07-13)3 unknown; Slovenská demokratická a kresťanská únia (2004-07-20--2009-07-13)3
lpv:translated text	". We live today in a world of incredible technical progress. But despite the advances that medicine has made, modern diseases still inspire fear. The use of progressive treatments, including gene- and cell-based therapies as well as tissue engineering, are innovative developments that give great hope to patients. There is no doubt about the huge potential of advanced medical therapies when it comes to providing revolutionary cures for serious conditions such as cancer, Parkinson’s disease and skin burns, and therefore I welcome the regulation of the European Commission aimed at harmonising procedures in this field across the EU, and ensuring that sufferers have safe cures for these serious ailments. The elimination of barriers on the European market will give patients greater access to existing cures through the Europe-wide licensing of these products. However, in order to maintain the underlying principles of the internal market and in the interest of its proper functioning, as well as to secure the legal bases, this regulation should apply only to cell-based products that may in the near future be actually introduced on the market and which do not arouse controversy. For this reason it is quite unacceptable to ignore the position of the Committee on Legal Affairs, which is the main body responsible for ethical issues in new technologies in the European Parliament. Finally I would like to congratulate rapporteur Mikolášik and thank him for his principled position on ethical matters and for his personal integrity based on the Oviedo Agreement and the Charter of Fundamental Rights."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph